natalizumab elan pharma
elan pharma international ltd. - natalizumab - doença de crohn - immunostimulants, - tratamento da activa moderada a grave doença de crohn para a redução de sintomas e sinais, e a indução e manutenção da sustentado de resposta e de remissão, em pacientes que não responderam, apesar de um completo e adequado de terapia com corticosteróides e imunossupressores; ou que são intolerantes ou que tenham contra-indicações médicas para tais terapias.
tysabri
biogen brasil produtos farmacÊuticos ltda - natalizumabe - outros produtos com acao imunoprotetora
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunossupressores - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
tysabri
biogen netherlands b.v. - natalizumab - esclerose múltipla - imunossupressores seletivos - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - fumarato de dimetilo - esclerose múltipla remitente-recorrente envio - imunossupressores - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
gilenya
novartis biociencias s.a - cloridrato de fingolimode - agente imunosupressor
entyvio
takeda pharma ltda. - vedolizumabe - imunosupressor
cloridrato de fingolimode
universidade federal do rio grande do norte - cloridrato de fingolimode - agente imunosupressor
emistin
ems s/a - fumarato de clemastina, dexametasona, acetato de dexametasona - anti-histaminicos sistemicos
mavenclad
merck s/a - cladribina - agente imunosupressor